Sugi Predict

Sugi Predict / Targets / MYLK2

MYLK2

Myosin light chain kinase 2, skeletal/cardiac muscle · Q9H1R3 · MYLK2 on Sugi Atlas →

2,492 patent compounds predicted against MYLK2, 1,728 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL17143243 SCHEMBL17143243 0.86 3/20
SCHEMBL17143449 SCHEMBL17143449 0.81 3/20
SCHEMBL17143249 SCHEMBL17143249 0.58 3/20
SCHEMBL17143338 SCHEMBL17143338 0.52 3/20
SCHEMBL16464884 SCHEMBL16464884 0.44 3/20
SCHEMBL3496512 SCHEMBL3496512 0.42 3/20
SCHEMBL3495479 SCHEMBL3495479 0.42 3/20
SCHEMBL15885857 SCHEMBL15885857 0.40 3/20
SCHEMBL17143384 SCHEMBL17143384 1.00 2/20
SCHEMBL17143305 SCHEMBL17143305 0.68 2/20
SCHEMBL17143271 SCHEMBL17143271 0.56 2/20
SCHEMBL3379898 SCHEMBL3379898 0.52 2/20
SCHEMBL3380654 SCHEMBL3380654 0.52 2/20
SCHEMBL4561042 SCHEMBL4561042 0.50 2/20
SCHEMBL10286422 SCHEMBL10286422 0.50 2/20
SCHEMBL1916209 SCHEMBL1916209 0.49 2/20
SCHEMBL13503332 SCHEMBL13503332 0.49 2/20
SCHEMBL13503393 SCHEMBL13503393 0.47 2/20
SCHEMBL5215950 SCHEMBL5215950 0.42 2/20
SCHEMBL14549704 SCHEMBL14549704 0.42 2/20

Clinical trials — most relevant to MYLK2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Cardiac REperfusion With Intralipid® at Reperfusion PHASE2/PHASE3UNKNOWN
Effects of Triiodothyronine (T3) in Ischemic Heart Failure PHASE1/PHASE2ACTIVE_NOT_RECRUITING
COSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure PHASE2COMPLETED
A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy PHASE2RECRUITING
Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy PHASE2RECRUITING
Evaluating MED2005 & Nitrostat Bioavailability PHASE1COMPLETED
Autologous Cultured Myoblasts (BioWhittaker) Transplanted Via Myocardial Injection PHASE1UNKNOWN
Genetic Analysis of African-Americans With High Blood Pressure nanCOMPLETED
Transcutaneous Functional Magnetic Muscle Stimulation in Critically Ill nanUNKNOWN
LVAD Conditioning for Cardiac Recovery nanRECRUITING
Effects of Whole Body Vibration and Resistance Exercise on Carotis Intima Media and Muscle Architecture in Hypertension nanCOMPLETED
Role of Amino Acids and Genetic Disorder in Pathogenesis of Heart Failure nanUNKNOWN
DNA/RNA Analysis of Blood and Skeletal Muscle in Patients Undergoing Cardiac Resynchronization Therapy (CRT) nanCOMPLETED
A Comparison of p53-induced Genes Activation in Patients With and Without Acute Myocardial Infarction nanCOMPLETED
Cardiac and Skeletal Muscle Energy Metabolism in Abnormal Growth Hormone States nanCOMPLETED
Pediatric Cardiomyopathy Mutation Analysis nanRECRUITING
Heart and Skeletal Muscle Problems in Neuroacanthocytosis nanCOMPLETED
Physical Activity and Sarcoma, Role and Impact on Outcome nanNOT_YET_RECRUITING
Multicenter Study of Immunoadsorption in Dilated Cardiomyopathy nanCOMPLETED
LIPCAR, Cuproptosis, and Α-SMA in the Pathogenesis of AMI and Remodeling nanNOT_YET_RECRUITING
Maintenance of Muscle Mass in Older People: the Negative Impact of Statin Therapy nanCOMPLETED
In Vivo Analysis of Muscle Stem Cells in Chronic and Acute Lower Limb Ischemia (MyostemIschemia) nanCOMPLETED
Hemodynamic Assessment of underLying myocyTe Function in Right Heart Failure nanRECRUITING
MicroRNA-1 (miRNA-1) and MicroRNA-133a (miRNA-133a) Levels After Acute Exercise in Ultimate Frisbee Athletes nanUNKNOWN
Genetics of Cardiovascular and Neuromuscular Disease nanRECRUITING
Early Detection of Cardiomyopathy by Speckle Echo, High Sensitive Troponin and Cardiac Ryanodine Receptors nanUNKNOWN
Observational Study on Cardiac Biomarkers Testing in Patients with Muscular Dystrophy Cardiomyopathy nanCOMPLETED
Signs and Symptoms Associated With Molecular Defects in Genetically Inherited Heart Disease nanCOMPLETED
B3 for NMD: Bench to Bedside and Back nanENROLLING_BY_INVITATION
T1 Mapping of Diffuse Myocardial Fibrosis in Congenital Heart Disease nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a MYLK2 binder may also engage these)

ProteinNameSimilarity
P20689 — 1.000 P20689 →
Q8VCR8 — 1.000 Q8VCR8 →
A4IFM7 — 1.000 A4IFM7 →
P07313 — 1.000 P07313 →
Q8BWQ5 — 0.997 Q8BWQ5 →
Q3UIZ8 — 0.995 Q3UIZ8 →
Q63553 — 0.993 Q63553 →
Q3ULB5 — 0.992 Q3ULB5 →
MKNK1 MAP kinase-interacting serine/threonine-protein kinase 1 0.991 landscape →
Q5R8Z4 — 0.991 Q5R8Z4 →
Q8VDU5 — 0.989 Q8VDU5 →
Q9GZR2 — 0.988 Q9GZR2 →
NOP2 28S rRNA (cytosine(4447)-C(5))-methyltransferase 0.988 landscape →
Q60700 — 0.988 Q60700 →
A6QP06 — 0.988 A6QP06 →
O70551 — 0.988 O70551 →
SNRK SNF-related serine/threonine-protein kinase 0.988 landscape →
Q68UT7 — 0.987 Q68UT7 →
Q8C0C0 — 0.987 Q8C0C0 →
Q66HE5 — 0.987 Q66HE5 →
Q924U5 — 0.987 Q924U5 →
KDM4B Lysine-specific demethylase 4B 0.987 landscape →
Q5DW34 — 0.987 Q5DW34 →
Q2PFD7 — 0.987 Q2PFD7 →
Q6DEW6 — 0.987 Q6DEW6 →
USP19 Ubiquitin carboxyl-terminal hydrolase 19 0.987 landscape →
O54988 — 0.986 O54988 →
Q9Z1J2 — 0.986 Q9Z1J2 →
Q6YY75 — 0.986 Q6YY75 →
Q9BQK8 — 0.986 Q9BQK8 →